Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors

Journal of Medicinal Chemistry

Volumn 55, Issue 11, 2012, Pages 5467-5482

  Leahy, James W ^a   Buhr, Chris A ^a   Johnson, Henry W B ^a   Kim, Byung Gyu ^a   Baik, Taegon ^a   Cannoy, Jonah ^a   Forsyth, Timothy P ^a   Jeong, Joon Won ^a   Lee, Matthew S ^a   Ma, Sunghoon ^a   Noson, Kevin ^a   Wang, Longcheng ^a   Williams, Matthew ^a   Nuss, John M ^a   Brooks, Eric ^a   Foster, Paul ^a   Goon, Leanne ^a   Heald, Nathan ^a   Holst, Charles ^a   Jaeger, Christopher ^a   Lam, Scott ^a   Lougheed, Julie ^a   Nguyen, Lam ^a   Plonowski, Arthur ^a   Song, Joanne ^a   Stout, Thomas ^a   Wu, Xiang ^a   Yakes, Michael F ^a   Yu, Peiwen ^a   Zhang, Wentao ^a   Lamb, Peter ^a   Raeber, Olivia ^a   more..

^a EXELIXIS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 6 [4 CHLORO 3 [N (2,3 DIFLUOROPHENYL)SULFAMOYL]PHENYL] N METHYLPYRAZINE 2 CARBOXAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; FEMALE; HIGH THROUGHPUT SCREENING; MOUSE; NONHUMAN; RAT; X RAY ANALYSIS;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CELL LINE; CLASS IB PHOSPHATIDYLINOSITOL 3-KINASE; CRYSTALLOGRAPHY, X-RAY; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; ISOENZYMES; LUMINESCENT MEASUREMENTS; MICE; MICROSOMES, LIVER; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHOSPHORYLATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; SULFONES;

EID: 84862301493     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300403a     Document Type: Article

References (57)

1. Vivanco, I.; Sawyers, C. L. The phosphatidylinositol 3-kinase AKT pathway in human cancer Nature Rev. Cancer 2002, 2, 489-501
2. Cantley, L. C. The phosphoinositide 3-kinase pathway Science 2002, 296, 1655-1657
3. Vanhaesebroeck, B.; Guillermet-Guibert, J.; Graupera, M.; Bilanges, B. The emerging mechanisms of isoform-specific PI3K signaling Nature Rev. Mol. Cell Biol. 2010, 11, 329-341
4. Vanhaesebroeck, B.; Leevers, S. J.; Ahmadi, K.; Timms, J.; Katso, R.; Driscoll, P. C.; Woscholski, R.; Parker, P. J.; Waterfield, M. D. Synthesis and function of 3-phosphorylated inositol lipids Annu. Rev. Biochem. 2001, 70, 535-602
5. Fruman, D. A.; Meyers, R. E.; Cantley, L. C. Phosphoinositide kinases Annu. Rev. Biochem. 1998, 67, 481-507
6. Krugmann, S.; Hawkins, P. T.; Pryer, N.; Braselmann, S. Characterizing the interactions between the two subunits of the p101/p110γ phosphoinositide 3-kinase and their role in the activation of this enzyme by Gβγ subunits J. Biol. Chem. 1999, 274, 17152-17158
7. Stephens, L.; Smrcka, A.; Cooke, F. T.; Jackson, T. R.; Sternweis, P. C.; Hawkins, P. T. A novel phosphoinositide 3 kinase activity in myeloid-derived cells is activated by G-protein βγ subunits Cell 1994, 77, 83-93
8. Stoyanov, B.; Volinia, S.; Hanck, T.; Rubio, I.; Loubtchenkov, M.; Malek, D.; Stoyanova, S.; Vanhaesebroeck, B.; Dhand, R.; Nurnberg, B.; Gierschik, P.; Seedorf, K.; Hsuan, J. J.; Waterfield, M. D.; Wetzker, R. Cloning and characterization of a G-protein activated human phosphoinositide 3-kinase Science 1995, 269, 690-693
9. Stephens, L. R.; Eguinoa, A.; Erdjument-Bromage, H.; Lui, M.; Cooke, F.; Coadwell, J.; Smrcka, A. S.; Thelen, M.; Cadwallader, K.; Tempst, P.; Hawkins, P. T. The Gβγ sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101 Cell 1997, 89, 105-114
10. Okkenhaug, K.; Vanhaesebroeck, B. PI3K in lymphocyte development, differentiation, and activation Nature Rev. Immumol. 2003, 3, 317-330
11. Wetzker, R.; Rommel, C. Phosphoinositide 3-kinases as targets for therapeutic intervention Curr. Pharm. Des. 2004, 10, 1915-1922
12. Foukas, L. C.; Claret, M.; Pearce, W.; Okkenhaug, K.; Meek, S.; Peskett, E.; Sancho, S.; Smith, A. J. H.; Withers, D. J.; Vanhaesebroeck, B. Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation Nature 2006, 441, 366-370
13. Samuels, Y.; Wang, Z.; Bardelli, A.; Silliman, N.; Ptak, J.; Szabo, S.; Yan, H.; Gazdar, A.; Powell, S. M.; Riggins, G. J.; Willson, J. K.; Markowitz, S.; Kinzler, K. W.; Vogelstein, B.; Velculescu, V. E. High frequency of mutations of the PIK3Ca gene in human cancers Science 2004, 304, 554
14. Ghigo, A.; Damilano, F.; Braccini, L.; Hirsch, E. PI3K inhibition in inflammation: Toward tailored therapies for specific diseases BioEssays 2010, 32, 185-196
15. Reif, K.; Okkenhaug, K.; Sasaki, T.; Penninger, J. M.; Vanhaesebroeck, B.; Cyster, J. G. Differential roles for phosphoinositide 3-kinases, p110γ and p110δ, in lymphocyte chemotaxis and homing J. Immunol. 2004, 173, 2236-2240
16. Laffargue, M.; Calvez, R.; Finan, P.; Trifilieff, A.; Barbier, M.; Altruda, F.; Hirsch, E.; Wymann, M. P. Phosphoinositide 3-kinase γ is an essential amplifier of mast cell function Immunity 2002, 16, 441-451
17. Martin, D.; Galisteo, R.; Molinolo, A. A.; Wetzker, R.; Hirsch, E.; Gutkind, J. S. PI3Kγ mediates kaposi's sarcoma-associated herpesvirus vGPCR-induced sarcomagenesis Cancer Cell 2011, 19, 805-813
18. Schmid, M. C.; Avraamides, C. J.; Dippold, H. C.; Franco, I.; Foubert, P.; Ellies, L. G.; Acevedo, L. M.; Manglicmot, J. R. E.; Song, X.; Wrasidlo, W.; Blair, S. L.; Ginsberg, M. H.; Cheresh, D. A.; Hirsch, E.; Field, S. J.; Varner, J. A. receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3Kγ, a single convergent point promoting tumor inflammation and progression Cancer Cell 2011, 19, 715-727
19. Gonzalez-Garcia, A.; Sanchez-Ruiz, J.; Flores, J. M.; Carrera, A. C. Phosphatidylinositol 3-kinase γ inhibition ameliorates inflammation and tumor growth in a model of colitis-associated cancer Gastroenterology 2010, 138, 1374-1383
20. Monterrubio, M.; Mellado, M.; Carrera, A. C.; Rodriguez-Frade, J. M. R.-F. PI3Kγ activation by CXCL12 regulates tumor cell adhesion and invasion Biochem. Biophys. Res. Commun. 2009, 388, 199-204
21. Attoub, S.; De Wever, O.; Bruyneel, E.; Mareel, M.; Gespach, C. The transforming functions of PI3-kinase-γ are linked to disruption of intercellular adhesion and promotion of cancer cell invasion Ann. N.Y. Acad. Sci. 2008, 1138, 204-213
22. Kobayashi, N.; Ueki, K.; Okazaki, Y.; Iwane, A.; Kubota, N.; Ohsugi, M.; Awazaw, M.; Kobayashi, M.; Sasako, T.; Kaneko, K.; Suzuki, M.; Nishikawa, Y.; Hara, K.; Yoshimura, K.; Koshima, I.; Goyama, S.; Murakami, K.; Sasaki, J.; Nagai, R.; Kurokawa, M.; Sasaki, T.; Kadowaki, A. Blockade of class IB phosphoinositide-3 kinase ameliorates obesity-induced inflammation and insulin resistance Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 5753-5758
23. Damilano, F.; Franco, I.; Perrino, C.; Schaefer, K.; Azzolino, O.; Carnevale, D.; Cifelli, G.; Carullo, P.; Ragona, R.; Ghigo, A.; Perino, A.; Lembo, G.; Hirsch, E. Distinct effects of leukocyte and cardiac phosphoinositide 3-kinase γ activity in pressure overload-induced cardiac failure Circulation 2001, 123, 391-399
24. Jin, R.; Song, Z.; Yu, S.; Piazza, A.; Nanda, A.; Penninger, J. M.; Granger, D. N.; Li, G. Phosphatidylinositol-3-kinase gamma plays a central role in blood-brain barrier dysfunction in acute experimental stroke Stroke 2011, 42, 2033-2044
25. Guo, D.; Thiyam, G.; Bodiga, S.; Kassiri, Z.; Oudit, G. Y. Uncoupling between enhanced excitation-contraction coupling and the response to heart disease: Lessons from the PI3Kγ knockout murine model J. Mol. Cell Cardiol. 2011, 50, 606-612
26. Siragusa, M.; Katare, R.; Meloni, M.; Damilano, F.; Hirsch, E.; Emanueli, C.; Madeddu, P. Involvement of phosphoinositide kinase γ in angiogenesis and healing of experimental myocardial infarction in mice Circ. Res. 2010, 106, 757-768
27. Seropian, I. M.; Abbate, A.; Toldo, S.; Harrington, J.; Smithson, L.; Ockaili, R.; Mezzaroma, E.; Damilano., F.; Hirsch, E.; Van Tassell, B. W. Pharmacologic inhibition of phosphoinositide 3-kinase gamma (PI3Kγ) promotes infarct resorption and prevents adverse cardiac remodeling after myocardial infarction in mice J. Cardiovasc. Pharm. 2010, 56, 651-658
28. Jin, R.; Yu, S.; Song, Z.; Quillin, J. W.; Deasis, D. P.; Penninger, J. M.; Nanda, A.; Granger, D. N.; Li, G. Phosphoinositide 3-kinase-gamma expression is upregulated in brain microglia and contributes to ischemia-induced microglial activation in acute experimental stroke Biochem. Biophys. Res. Commun. 2010, 399, 458-464
29. Passos, G. F.; Figueiredo, C. P.; Prediger, R. D. S.; Silva, K. A. B. S.; Siqueira, J. M.; Duarte, F. S.; Leal, P. C.; Medeiros, R.; Calixto, J. B. Involvement of phosphoinositide 3-kinase γ in the neuro-inflammatory response and cognitive impairments induced by β-amyloid 1-40 peptide in mice Brain Behav. Immun. 2010, 24, 493-501
30. Maira, S. M.; Finan, P.; Garcia-Echeverria, C. From the bench to the bed side: PI3K pathway inhibitors in clinical development Curr. Top. Microbiol. Immunol. 2011, 347, 209-239
31. Shapiro, G.; Kwak, E.; Baselga, J.; Rodon, J.; Scheffold, C.; Laird, A. D.; Bedell, C.; Edelman, G. Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors. Presented at ASCO 2009 Annual Meeting, Orlando, FL, May 29-June 2, 2009; Abstract 3500
32. Papadopoulos, K. P.; Markman, B.; Tabernero, J.; Patnaik, A.; Heath, E. I.; DeCillis, A.; Laird, D.; Aggarwal, S. K.; Nguyen, L.; LoRusso, P. M. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765, administered orally to patients (pts) with advanced solid tumors. Presented at ASCO 2009 Annual Meeting, Chicago, IL, May 30-June 3, 2008; Abstract 3510
33. Rückle, T.; Schwarz, M. K.; Rommel, C. PI3Kγ inhibition: towards an 'aspirin of the 21st century'? Nat. Rev. Drug Discovery 2006, 5, 903-918
34. Rommel, C.; Camps, M.; Ji, H. PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat. Rev. Drug Discovery 2007, 7, 191-201
35. Ameriks, M. K.; Venable, J. D. Small Molecule inhibitors of phosphoinositide 3-kinase (PI3K) δ and γ Curr. Top. Med. Chem. 2009, 9, 738-753
36. Pacold, M. E.; Suire, S.; Perisic, O.; Lara-Gonzalez, S.; Davis, C. T.; Walker, E. H.; Hawkins, P. T.; Stephens, L.; Eccleston, J. F.; Williams, R. L. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase γ Cell 2000, 103, 931-943
37. Suire, S.; Hawkins, P.; Stephens, L. Activation of phosphoinositide 3-kinase γ by Ras Curr. Biol. 2002, 12, 1068-1075
38. Bondeva, T.; Pirola, L.; Bulgarelli-Leva, G.; Rubio, I.; Wetzker, R.; Wymann, M. P. Bifurcation of lipid and protein kinase signals of PI3Kγ to the protein kinases PKB and MAPK Science 1998, 282, 293-296
39. Lopez-Ilasaca, M.; Gutkind, J. S.; Wetzker, R. Phosphoinositide 3-kinase γ is a mediator of Gβγ-dependent Jun kinase activation J. Biol. Chem. 1998, 273, 2505-2508
40. Li, Z.; Jiang, H.; Xie, W.; Zhang, Z.; Smrcka, A. V.; Wu, D. Roles of PLC-β2 and -β3 and PI3Kγ in chemoattractant-mediated signal transduction Science 2000, 287, 1046-1049
41. Hirsch, E.; Katanaev, V. L.; Garlanda, C.; Azzolino, O.; Pirola, L.; Silengo, L.; Sozzani, S.; Mantovani, A.; Altruda, F.; Wymann, M. P. Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation Science 2000, 287, 1049-1053
42. Sasaki, T.; Irie-Sasaki, J.; Jones, R. G.; Oliveira-dos-Santos, A. J.; Stanford, W. L.; Bolon, B.; Wakeham, A.; Itie, A.; Bouchard, D.; Kozieradzki, I.; Joza, J.; Mak, T. W.; Ohashi, P. S.; Suzuki, A.; Penninger, J M. Function of PI3Kγ in thymocyte development, T cell activation, and neutrophil migration Science 2000, 287, 1040-1046
43. Camps, M.; Rückle, T.; Ji, H.; Ardissone, V.; Rintelen, F.; Shaw, J.; Ferrandi, C.; Chabert, C.; Gillieron, C.; Françon, B.; Martin, T.; Gretener, D.; Perrin, D.; Leroy, D.; Vitte, P. A.; Hirsch, E.; Wymann, M. P.; Cirillo, R.; Schwarz, M. K.; Rommel, C. Blockade of PI3Kγ suppresses joint inflammation and damage in a murine model of rheumatoid arthritis Nature Med. 2005, 11, 936-943
44. Pomel, V.; Klicic, J.; Covini, D.; Church, D. D.; Shaw, J. P.; Roulin, K.; Burgat-Charvillon, F.; Valognes, D.; Camps, M.; Chabert, C.; Gillieron, C.; Françon, B.; Perrin, D.; Leroy, D.; Gretener, D.; Nichols, A.; Vitte, P. A.; Carboni, S.; Rommel, C.; Schwarz, M. K.; Rückle, T. Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase γ J. Med. Chem. 2006, 49, 3857-3871
45. Buhr, C. A.; Baik, T.-G.; Sunghoon, M.; Tesfai, Z.; Wang, L.; Co, E. W.; Epshteyn, S.; Kennedy, A. R.; Chen, B.; Dubenko, L.; Anand, N. K.; Tsang, T. H.; Nuss, J. M.; Peto, C. J.; Rice, K. D.; Ibrahim, M. A.; Schnepp, K. L.; Shi, X.; Leahy, J. W.; Chen, J.; Dalrymple, L. E.; Forsyth, T. P.; Huynh, T. P.; Mann, G.; Mann, L. W.; Takeuchi, C. S.; Lamb, P.; Matthews, D. J.; Miller, N. Protein Kinase Modulators and Methods of Use. PCT Int. Appl. WO0309329A2, 2003.
46. Sundstrom, T. J.; Anderson, A. C.; Wright, D. L. Inhibitors of phosphoinositide-3-kinase: a structure-based approach to understanding potency and selectivity Org. Biomol. Chem. 2009, 7, 840-850
47. Walker, E. H.; Perisic, O.; Ried, C.; Stephens, L.; Williams, R. L. Structural insights into phosphoinositide 3-kinase catalysis and signalling Nature 1999, 402, 313-320
48. Ali, K.; Camps, M.; Pearce, W. P.; Ji, H.; Kuehn, N.; Pasquali, C.; Chabert, C.; Rommel, C.; Vanhaesebroeck, B. Isoform-specific functions of phosphoinositide 3-kinases: p110δ but not p110γ promotes optimal allergic responses in vivo J. Immunol. 2008, 180, 2538-2544
49. Folkes, A. J.; Ahmadi, K.; Alderton, W. K.; Alix, S.; Baker, S. J.; Box, G.; Chuckowree, I. S.; Clarke, P. A.; Depledge, P.; Eccles, S. A.; Friedman, L. S.; Hayes, A.; Hancox, T. C.; Kugendradas, A.; Lensun, L.; Moore, P.; Olivero, A. G.; Pang, J.; Patel, S.; Pergl-Wilson, G. H.; Raynaud, F. I.; Robson, A.; Saghir, N.; Salphati, L.; Sohal, S.; Ultsch, M. H.; Valenti, M.; Wallweber, H. J.; Wan, N. C.; Wiesmann, C.; Workman, P.; Zhyvoloup, A.; Zvelebil, M. J.; Shuttleworth, S. J. The Identification of 2-(1 H -indazol-4-yl)-6-(4- methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer J. Med. Chem. 2008, 51, 5522-5532
50. Gendreau, S. B.; Ventura, R.; Keast, P.; Laird, A. D.; Yakes, F. M; Zhang, W.; Bentzien, F.; Cancilla, B.; Lutman, J.; Chu, F.; Jackman, L.; Shi, Y.; Yu, P.; Wang, J.; Aftab, A. T.; Jaeger, C. T.; Meyer, S. M.; De Costa, A.; Engell, K.; Chen, J.; Martini, J. F.; Joly, A. H. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647 Clin. Cancer Res. 2007, 13, 3713-3723
51. Qian, F.; Engst, S.; Yamaguchi, K.; Yu, P.; Won, K. A.; Mock, L.; Lou, T.; Tan, J.; Li, C.; Tam, D.; Lougheed, J.; Yakes, M. F.; Bentzien, F.; Xu, W.; Zaks, T.; Wooster, R.; Greshock, J.; Joly, A. H. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases Cancer Res. 2009, 69, 8009-8016
52. Zoncu, R.; Efayan, A.; Sabatini, D. M. mTOR: from growth signal integration to cancer, diabetes and ageing Nature Rev. Mol. Cell Biol. 2011, 12, 21-35
53. Adams, N. D.; Burgess, J. L.; Darcy, M. G.; Donatelli, C. A.; Knight, S. D.; Newlander, K. A.; Ridgers, L.; Sarpong, M.; Schmidt, S. J. Preparation of Quinoline Derivatives as PI3 Kinase Inhibitors. PCT Int. Appl. WO144463A1, 2008.
54. Harris, K. J.; Lang, H.-J.; Mathew, R. M.; Shimshock, S. J.; Nieduzak, T. R.; Jackson, S.; Yang, Z.; Bordeau, K. J. 2-Phenyl-indoles as Prostoglandin D2 Receptor Antagonists. PCT Int. Appl. WO2006081343, 2006.
55. Ibrahim, M. A.; Johnson, H. W. B.; Jeong, J. W.; Lewis, G. L.; Shi, X.; Noguchi, R. T.; Williams, M.; Leahy, J. W.; Nuss, J. M.; Woolfrey, J.; Banica, M.; Bentzien, F.; Chou, Y.-C.; Gibson, A.; Heald, N.; Lamb, P.; Mattheakis, L.; Matthews, D.; Shipway, A.; Wu, X.; Zhang, W.; Zhou, S.; Shankar, G. Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists J. Med. Chem. 2012, 55, 1368-1381
56. Munagala, N.; Nguyen, S.; Lam, W.; Lee, J.; Joly, A.; McMillan, K.; Zhang, W. Identification of small molecule ceramide kinase inhibitors using a homogeneous chemiluminescence high throughput assay Assay Drug Dev. Technol. 2007, 5, 65-73
57. Walker, E. H.; Pacold, M. E.; Perisic, O.; Stephens, L.; Hawkins, P. T.; Wymann, M. P.; Williams, R. L. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine Mol. Cell 2000, 6, 909-919